Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

orporate collaborations; potential delays; uncertainties related to early stage of technology and product development; uncertainties as to the requirement that a drug be found to be safe and effective after extensive clinical trials and the possibility that the results of such trials, if completed, will not establish the safety or efficacy of our products; uncertainties as to future expense levels and the possibility of unanticipated costs or expenses or cost overruns; the possibility that opportunities will arise that require more cash than presently anticipated and other uncertainties related to predictions of future cash requirements; and other risks and uncertainties which may not be described herein. Certain of these factors and other factors are described in detail in the Company's Annual Information Form and Annual Report on Form 20-F for and other filings with the Canadian securities regulatory authorities and the U.S. Securities & Exchange Commission.

Forward-looking statements are based on our current expectations and MIGENIX assumes no obligations to update such information to reflect later events or developments.

The Toronto Stock Exchange has not reviewed and does not accept

responsibility for the adequacy or accuracy of this release.

CONTACT: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666 Ext. 233, aayres@migenix.com; Dian Griesel, Ph.D., Investor Relations Group, Tel: (212) 825-3210, Theproteam@aol.com


'/>"/>
SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... (PRWEB) October 30, 2014 Two ... America were hosted by Charm Sciences at its ... their week in the US, the participants discussed ... control, hygiene management, and process verification, and received ... , This was the first visit to the ...
(Date:10/31/2014)... October 31, 2014 Following the successful ... free learning webinar to introduce its new product and ... and biostatisticians. , Launched in September, Formedix On Demand ... of clinical trial automation tools. For the first time, ... browser. And by introducing Formations – a revolutionary new ...
(Date:10/31/2014)... The report "Dairy Alternative (Beverage) Market ... Sweetened, Unsweetened), Channel (Supermarket, Health Store, Pharmacy, Convenience ... to 2018," defines and segments the dairy alternative ... revenue and volume for plant-based dairy alternative beverages. ... $14 Billion by 2018 with the Asia-Pacific region ...
(Date:10/31/2014)... ENVIRON , an international ... that Dr. Harvey Clewell III has rejoined the ... closely with senior professionals in ENVIRON’s Health Sciences ... at The Hamner Institutes for Health Sciences (The ... he is Director, Center for Human Health Assessment. ...
Breaking Biology Technology:Charm Sciences Hosts Executives from Latin America for Dairy Safety Executive Seminar 2Formedix to Introduce "Revolutionary" Clinical Trial Automation Software with Learning Webinar 2Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 2Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 3Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 4Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3
... ST PETER PORT, Guernsey and LONDON, July 6 ... to Drive Novel Antibiotics Platform Addressing,Areas of Major Unmet Need, ... Celtic Pharma Holdings Advisors LLP ("CPHA"), the advisor ... ("CP2"), today announces its,investment in a majority shareholding in Novacta ...
... NEW BRUNSWICK, N.J., July 3 Johnson & Johnson (NYSE: ... its tender offer for all outstanding shares of common stock of ... (Eastern time) on July 2, 2009. The offer was conducted ... Merger Sub, Inc. , , The depositary for the tender ...
... , PHOENIX, July 2 As many as ... with an eating disorder because they,re ashamed to admit they ... Eating and Anxiety Disorders . Healthcare professionals, family members ... in males that may signify an eating disorder. Therefore, effective ...
Cached Biology Technology:Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited 2Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited 3Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited 4Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited 5Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology 2Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology 3Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology 4Remuda Ranch Programs for Eating and Anxiety Disorders Reports Need for Increasing Awareness of Eating Disorders in Males 2
(Date:10/31/2014)... good for attracting species, but it may not be enough ... study has found. , The researchers surveyed two types of ... abundance of two insects that interact with them. They found ... and black walnut, they didn,t find a corresponding abundance of ... the walnuts and black cherries and a type of wasp ...
(Date:10/31/2014)... 30, 2014  HITLAB SM , a healthcare ... its inaugural HITLAB Innovators Summit SM on ... HITLAB will partner with the Clinton Foundation,s Health ... ProtoHack, Columbia Business School Alumni Club of ... Engineering and Operations Research, bringing together leaders in ...
(Date:10/30/2014)... 2014—Oligonucleotide-based therapeutics present unique challenges when it comes ... developmental harm. New consensus guidelines for toxicity testing ... biological characteristics of these novel biopharmaceuticals are presented ... journal from Mary Ann Liebert, Inc. publishers ... Nucleic Acid Therapeutics website until November ...
Breaking Biology News(10 mins):Green spaces don't ensure biodiversity in urban areas 2HITLAB Announces Inaugural HITLAB Innovators Summit 2HITLAB Announces Inaugural HITLAB Innovators Summit 3New guidelines for reproductive & developmental toxicity testing of oligonucleotide drugs 2
... Institute of Nanoscience have discovered how to use the ... a chip. Based on this, they built a transport ... individually. To demonstrate this, the Delft researchers sorted the ... the University of Florida has called the Delft discovery ...
... working at the University of Bristol has found a ... food poisoning. Their work is reported in Nature Medicine. ... shown that one particular antibiotic ? fosfomycin ?can treat ... laboratory conditions. , Because it was not effective in ...
... Wegener Institute for Polar and Marine Research observed ... began in Ny-Ålesund on Svalbard. Monitoring instruments displayed ... found. Aerosols from eastern Europe have been transported ... large-scale weather situation. , Usually the air ...
Cached Biology News:Biological motors sort molecules one by one on a chip 2Record air pollution above the Arctic 2